Request Consultation
search-icon
Download Videssa Guide

Provista Blog > Does Dense Breast Tissue Pose the Same Diagnostic Challenge Using Liquid Biopsy as it Does for Imaging?

Provista Blog

Does Dense Breast Tissue Pose the Same Diagnostic Challenge Using Liquid Biopsy as it Does for Imaging?

Posted by Provista Diagnostics on November 15, 2017
Share:     

As you may know, the topic of breast density is gaining attention in the breast cancer space. Unfortunately, there is still not a clear solution to address the density dilemma. Advanced imaging options for women with heterogeneously and extremely dense breast may still create challenges for a healthcare provider in the form of false positive and false negative results. As with all breast cancers, the healthcare community is trying to determine which suspicious lesions are cancer and which are benign – made particularly challenging when further confounded by dense breast tissue.

Aiming to help address the breast density issue, this study examined the ability of Videssa®Breast to rule out breast cancer in women with dense breasts. Videssa Breast is a protein-based blood test that when used in conjunction with imaging improves overall breast cancer detection.

Key takeaway:

This new study demonstrates that a blood test used with imaging can improve overall breast cancer detection, regardless of breast density. By reading biochemical information rather than images, Videssa Breast can help reliably rule out cancer in women with dense breasts when imaging yields a suspicious result.

dense breast info-1.png

 

Clinical Challenge:

  • For women with dense breasts, the resolution on imaging is not always clear enough to detect or rule out breast cancer

  • 10 percent of women have extremely dense breasts and are 10 times more likely to have an abnormality missed on mammogram

The Study:

  • Two prospective clinical trials to evaluate the performance of Videssa Breast, a blood based multi-protein biomarker test, to detect breast cancer in women under 50 with abnormal imaging (BI-RADS 3 and 4)

Findings:

  • The differences were not statistically significant

  • The performance of Videssa Breast was not impacted by dense breast tissue

Implications:

  • The consistency of results in women with dense and non-dense breasts suggest that Videssa Breast is not impacted by increased breast density

  • When used in conjunction with breast imaging, clinicians have a new tool to assess women with dense breasts and reduce the use of biopsy to rule out cancer in women with suspicious findings

dense breast info-5-777795-edited.png

 

Finally, we have a blood test that can be used in combination of standard-of-care to assist healthcare providers manage extremely and heterogeneously dense breast patients with BI-RADS 3s and 4s.  Videssa Breast can provide a complete biochemical assessment to help determine the most appropriate next steps for the total management of the woman’s breast care.  

To receive information like this about the latest studies in breast cancer detection, sign-up for our mailing list here.

Denisty Manuscript CTA
Provista Diagnostics

Provista Diagnostics

At Provista Diagnostics, our mission is to develop world-class diagnostic tests for indications in breast and gynecologic cancers. As a leading diagnostics company, our aim is to create, produce and market innovative solutions for unmet clinical needs. Our products and services help to diagnose diseases and inform better clinical decisions, thus enhancing women’s health and quality of life. We do this in a responsible and ethical manner with a commitment to excellence in every aspect of our business.